Prefer Glenmark, Ipca Labs, says PN Vijay

One can prefer Glenmark Pharma and Ipca Labs, says PN Vijay, Portfolio Manager.

Vijay told CNBC-TV18, "Everything looks interesting in pharma but the midcaps have fallen a lot. It has sort of been lost in the market because all midcaps have fallen. I think better bargains are going to be available in the midcaps as compared to Sun Pharma or Dr Reddys."
He further added, "My own favourites for a long time in this have been Glenmark and Ipca Labs. They have a very good business model, they are research driven, they are gaining market share and their products are getting approval, the whole lot of it. So I think one won’t lose any money and probably make market outperformance by investing into Glenmark and Ipca Labs in the ongoing rally in midcaps that we are seeing."